SAN JOSE, Calif.--(BUSINESS WIRE)--LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX) and co-developer of ResearchKit-enabled app Asthma Health, today announced a new service to develop custom smartphone apps and research studies for partners worldwide.
Through the new service, LifeMap offers clients its deep expertise in medical science, consumer behavior, app analytics, and design. LifeMap then adds the client’s own unique expertise to the mix and guides the development, from concept to completion, of a new research or care app and, optionally, a scientific study.
As the only commercial developer to participate in the launch of Apple’s ResearchKit, LifeMap Solutions has garnered worldwide attention for creating engaging, innovative, and data-driven mobile health (mHealth) apps. LifeMap has worked closely with innovative research institutions and commercial organizations such as the Icahn School of Medicine at Mount Sinai, Stanford University School of Medicine, the Mount Sinai – National Jewish Health Respiratory Institute, and 23andMe.
“The ResearchKit revolution has struck a chord in the scientific and medical industries,” said Corey Bridges, CEO of LifeMap Solutions. “Research institutions, hospitals, and multinational pharmaceutical companies have asked us to help them. They’ve expressed a strong interest in breaking out of the ‘bricks and mortar’ constraints of traditional research studies and care tools. For research studies in particular, the benefits of using mHealth best practices are extremely compelling: recruiting thousands of study participants nationally or even internationally, obtaining consent through the friendly interface of the iPhone, and passively collecting participants’ health information. We’re entering a new era of accelerated scientific discovery. And, with Apple’s new CareKit platform, I expect we’ll see a similar revolution in medical care. Thanks to our team’s unique skillset and experience, I believe LifeMap Solutions will play a market-leading role as the mHealth field evolves.”
In building research apps, LifeMap’s new app-design and creation service follows a simple five-step process. The LifeMap Solutions team works with partners to:
- Plan - integrate their design into a secure mHealth platform and build a fully customized app that satisfies study and consent requirements, delivered on time and on budget.
- Review - work with a partner’s Institutional Review Board (IRB) to facilitate approval of research studies conducted through smartphones.
- Build - transform traditional research elements into visually compelling and engaging apps.
- Launch - facilitate the app’s launch by working with an institution’s own app-publishing team or submitting the app directly into the App Store.
- Publish - help to best utilize the data to further research and transform findings into scientific articles and peer-reviewed publications with a team of highly skilled data scientists.
Organizations interested in working with LifeMap Solutions can learn more and contact the company here.
About LifeMap Solutions, Inc.
LifeMap Solutions develops innovative digital health solutions by integrating health and wellness information with care team guidance into a secure mHealth platform to deliver digital health solutions that empower patients to make better choices to achieve optimal health outcomes. LifeMap Solutions is a subsidiary of BioTime, Inc., and is headquartered in San Jose, California. For more information, please visit www.lifemap-solutions.com.
BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent stem cell assets. The foundation of our core therapeutic technology platform is pluripotent stem cells that are capable of becoming any of the cell types in the human body. Pluripotent stem cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent stem cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.